Incidence, angiographic and clinical predictors, and impact of stent thrombosis: a 6-year survey of 6,545 consecutive patients.
Coronary stent thrombosis
Drug-eluting stent
Dual antiplatelet therapy
Journal
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
ISSN: 1568-5888
Titre abrégé: Neth Heart J
Pays: Netherlands
ID NLM: 101095458
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
pubmed:
22
3
2019
medline:
22
3
2019
entrez:
22
3
2019
Statut:
ppublish
Résumé
We sought to determine the incidence, angiographic predictors, and impact of stent thrombosis (ST). Given the high mortality after ST, this study emphasises the importance of ongoing efforts to identify angiographic predictors of ST. All consecutive patients with angiographically confirmed ST between 2010 and 2016 were 1:4 matched for (1) percutaneous coronary intervention (PCI) indication and (2) index date ±6 weeks to randomly selected controls. Index PCI angiograms were reassessed by two independent cardiologists. A multivariable conditional logistic regression model was built to identify independent predictors of ST. Of 6,545 consecutive patients undergoing PCI, 55 patients [0.84%, 95% confidence interval (CI) 0.63-1.10%] presented with definite ST. Multivariable logistic regression identified dual antiplatelet therapy (DAPT) non-use as the strongest predictor of ST (odds ratio (OR) 10.9, 95% CI 2.47-48.5, p < 0.001), followed by: stent underexpansion (OR 5.70, 95% CI 2.39-13.6, p < 0.001), lesion complexity B2/C (OR 4.32, 95% CI 1.43-13.1, p = 0.010), uncovered edge dissection (OR 4.16, 95% CI 1.47-11.8, p = 0.007), diabetes mellitus (OR 3.23, 95% CI 1.25-8.36, p = 0.016), and residual coronary artery disease at the stent edge (OR 3.02, 95% CI 1.02-8.92, p = 0.045). ST was associated with increased rates of mortality as analysed by Kaplan-Meier estimates (27.3 vs 11.3%, p ST remains a serious complication following PCI with a high rate of mortality. DAPT non-use was associated with the highest risk of ST, followed by various angiographic parameters and high lesion complexity.
Sections du résumé
OBJECTIVE
OBJECTIVE
We sought to determine the incidence, angiographic predictors, and impact of stent thrombosis (ST).
BACKGROUND
BACKGROUND
Given the high mortality after ST, this study emphasises the importance of ongoing efforts to identify angiographic predictors of ST.
METHODS
METHODS
All consecutive patients with angiographically confirmed ST between 2010 and 2016 were 1:4 matched for (1) percutaneous coronary intervention (PCI) indication and (2) index date ±6 weeks to randomly selected controls. Index PCI angiograms were reassessed by two independent cardiologists. A multivariable conditional logistic regression model was built to identify independent predictors of ST.
RESULTS
RESULTS
Of 6,545 consecutive patients undergoing PCI, 55 patients [0.84%, 95% confidence interval (CI) 0.63-1.10%] presented with definite ST. Multivariable logistic regression identified dual antiplatelet therapy (DAPT) non-use as the strongest predictor of ST (odds ratio (OR) 10.9, 95% CI 2.47-48.5, p < 0.001), followed by: stent underexpansion (OR 5.70, 95% CI 2.39-13.6, p < 0.001), lesion complexity B2/C (OR 4.32, 95% CI 1.43-13.1, p = 0.010), uncovered edge dissection (OR 4.16, 95% CI 1.47-11.8, p = 0.007), diabetes mellitus (OR 3.23, 95% CI 1.25-8.36, p = 0.016), and residual coronary artery disease at the stent edge (OR 3.02, 95% CI 1.02-8.92, p = 0.045). ST was associated with increased rates of mortality as analysed by Kaplan-Meier estimates (27.3 vs 11.3%, p
CONCLUSIONS
CONCLUSIONS
ST remains a serious complication following PCI with a high rate of mortality. DAPT non-use was associated with the highest risk of ST, followed by various angiographic parameters and high lesion complexity.
Identifiants
pubmed: 30895527
doi: 10.1007/s12471-019-1253-2
pii: 10.1007/s12471-019-1253-2
pmc: PMC6533324
doi:
Types de publication
Journal Article
Langues
eng
Pagination
321-329Subventions
Organisme : none
ID : none
Références
Lancet. 2002 May 11;359(9318):1686-9
pubmed: 12020548
Eur Heart J. 2005 Jun;26(12):1180-7
pubmed: 15728650
JAMA. 2005 May 4;293(17):2126-30
pubmed: 15870416
Circulation. 2006 Feb 28;113(8):1108-13
pubmed: 16490815
Circulation. 2006 Jun 20;113(24):2803-9
pubmed: 16769908
Lancet. 2007 Feb 24;369(9562):667-78
pubmed: 17321312
Circulation. 2007 Aug 14;116(7):745-54
pubmed: 17664375
J Am Coll Cardiol. 2008 Mar 11;51(10):986-90
pubmed: 18325436
J Am Coll Cardiol. 2008 Jun 24;51(25):2396-402
pubmed: 18565395
Circulation. 2009 Feb 10;119(5):687-98
pubmed: 19171852
Circulation. 2009 Feb 24;119(7):987-95
pubmed: 19204304
J Am Coll Cardiol. 2009 Apr 21;53(16):1399-409
pubmed: 19371823
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
JACC Cardiovasc Interv. 2009 Oct;2(10):989-94
pubmed: 19850260
Am Heart J. 2010 Apr;159(4):672-6
pubmed: 20362728
Circulation. 2010 Sep 7;122(10):1017-25
pubmed: 20733100
JACC Cardiovasc Interv. 2011 Sep;4(9):974-81
pubmed: 21939937
JAMA. 2011 Oct 26;306(16):1765-74
pubmed: 22028352
Lancet. 2013 Nov 23;382(9906):1714-22
pubmed: 24004642
Circulation. 1990 Oct;82(4):1193-202
pubmed: 2401060
Circulation. 2014 Jan 28;129(4):463-70
pubmed: 24281330
JACC Cardiovasc Interv. 2013 Dec;6(12):1267-74
pubmed: 24355117
Am Heart J. 2015 Feb;169(2):249-56
pubmed: 25641534
Eur Heart J. 2015 Dec 14;36(47):3346-55
pubmed: 26242713
JAMA. 2015 Nov 24;314(20):2155-63
pubmed: 26556051
Eur Heart J. 2016 Apr 14;37(15):1208-16
pubmed: 26757787
Catheter Cardiovasc Interv. 2017 Jan;89(1):26-35
pubmed: 26813732
J Am Coll Cardiol. 2016 Oct 25;68(17):1851-1864
pubmed: 27595509
Lancet. 2016 Nov 26;388(10060):2618-2628
pubmed: 27806900
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
JACC Cardiovasc Interv. 2017 Aug 28;10(16):1621-1630
pubmed: 28838471
Circulation. 2018 Jun 12;137(24):2635-2650
pubmed: 29891620